Hi Mabtech!
I found the following question and answer in your FAQ section:
21. Why is the addition of anti-CD28 recommended in the FluoroSpot protocol but not in the ELISpot protocol?
In FluoroSpot analysis the possible biological effect of cytokine capture by several coated antibodies has to be taken into consideration. The presence of of e.g. IL-2 capture mAbs may result in reduced activation of T cells. To circumvent the attenuating effect of IL-2 capture, anti-CD28 mAb can be added to provide a co-stimulatory signal to antigen-specific responses by binding to CD28 on T cells. The co-stimulatory effects of anti-CD28 mAb, as well as a possible impact on non-specific spots can be assessed by comparing cells cultured with or without anti-CD28 mAb.
This FAQ answer left me with some questions unanswered. For example, why does the IFNg/Granzyme B Fluorospot kit include an anti-CD28 stimulatory mAb, whereas it is not included in the IL-2 ELISpotPLUS kit? Couldn't the IL-2 capture mAbs in the ELISpot kit also lead to reduced activation of T cells? And is there really any risk for reduced activation of T cells when capturing IFNg and Granzyme B in the mentioned Flurospot kit? Please clarify your rationale further.
Thank you for top-of-the-line products otherwise.
Regards!
Peter